Targeting G-quadruplex DNA Structures by EMICORON has a strong antitumor efficacy against advanced models of human colon cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Targeting G-quadruplex DNA Structures by EMICORON has a strong antitumor efficacy against advanced models of human colon cancer. / Porru, Manuela; Artuso, Simona; Salvati, Erica; Bianco, Armandodoriano; Franceschin, Marco; Diodoro, Maria Grazia; Passeri, Daniela; Orlandi, Augusto; Savorani, Francesco; D'Incalci, Maurizio; Biroccio, Annamaria; Leonetti, Carlo.
In: Molecular Cancer Therapeutics, Vol. 14, No. 11, 2015, p. 2541-2551.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Targeting G-quadruplex DNA Structures by EMICORON has a strong antitumor efficacy against advanced models of human colon cancer
AU - Porru, Manuela
AU - Artuso, Simona
AU - Salvati, Erica
AU - Bianco, Armandodoriano
AU - Franceschin, Marco
AU - Diodoro, Maria Grazia
AU - Passeri, Daniela
AU - Orlandi, Augusto
AU - Savorani, Francesco
AU - D'Incalci, Maurizio
AU - Biroccio, Annamaria
AU - Leonetti, Carlo
N1 - ©2015 American Association for Cancer Research.
PY - 2015
Y1 - 2015
N2 - We previously identified EMICORON as a novel G-quadruplex (G4) ligand showing high selectivity for G4 structures over the duplex DNA, causing telomere damage and inhibition of cell proliferation in transformed and tumor cells. Here, we evaluated the antitumoral effect of EMICORON on advanced models of human colon cancer that could adequately predict human clinical outcomes. Our results showed that EMICORON was well tolerated in mice, as no adverse effects were reported, and a low ratio of sensitivity across human and mouse bone marrow cells was observed, indicating a good potential for reaching similar blood levels in humans. Moreover, EMICORON showed a marked therapeutic efficacy, as it inhibited the growth of patient-derived xenografts (PDX) and orthotopic colon cancer and strongly reduced the dissemination of tumor cells to lymph nodes, intestine, stomach, and liver. Finally, activation of DNA damage and impairment of proliferation and angiogenesis are proved to be key determinants of EMICORON antitumoral activity. Altogether, our results, performed on advanced experimental models of human colon cancer that bridge the translational gap between preclinical and clinical studies, demonstrated that EMICORON had an unprecedented antitumor activity warranting further studies of EMICORON-based combination treatments. Mol Cancer Ther; 14(11); 2541-51. ©2015 AACR.
AB - We previously identified EMICORON as a novel G-quadruplex (G4) ligand showing high selectivity for G4 structures over the duplex DNA, causing telomere damage and inhibition of cell proliferation in transformed and tumor cells. Here, we evaluated the antitumoral effect of EMICORON on advanced models of human colon cancer that could adequately predict human clinical outcomes. Our results showed that EMICORON was well tolerated in mice, as no adverse effects were reported, and a low ratio of sensitivity across human and mouse bone marrow cells was observed, indicating a good potential for reaching similar blood levels in humans. Moreover, EMICORON showed a marked therapeutic efficacy, as it inhibited the growth of patient-derived xenografts (PDX) and orthotopic colon cancer and strongly reduced the dissemination of tumor cells to lymph nodes, intestine, stomach, and liver. Finally, activation of DNA damage and impairment of proliferation and angiogenesis are proved to be key determinants of EMICORON antitumoral activity. Altogether, our results, performed on advanced experimental models of human colon cancer that bridge the translational gap between preclinical and clinical studies, demonstrated that EMICORON had an unprecedented antitumor activity warranting further studies of EMICORON-based combination treatments. Mol Cancer Ther; 14(11); 2541-51. ©2015 AACR.
U2 - 10.1158/1535-7163.MCT-15-0253
DO - 10.1158/1535-7163.MCT-15-0253
M3 - Journal article
C2 - 26304235
VL - 14
SP - 2541
EP - 2551
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
SN - 1535-7163
IS - 11
ER -
ID: 147987233